New pill aims to quiet schizophrenia psychosis in weeks
NCT ID NCT05227690
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tested two doses of emraclidine (10 mg and 30 mg daily) against a placebo in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. The study lasted 6 weeks and measured symptom changes using a standard rating scale. The goal was to see if emraclidine can safely and effectively reduce symptoms like hallucinations and delusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Emraclidine (CVL-231)
What this could lead to
If successful, emraclidine could offer a new option to quickly reduce severe psychotic symptoms in people with schizophrenia.
What could go wrong
This is an early Phase 2 trial with a small number of participants and a short 6-week duration. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim, California
Anaheim, California, 92805-5854, United States
-
Atlanta, Georgia
Atlanta, Georgia, 30328-4018, United States
-
DeSoto, Texas
DeSoto, Texas, 75115-2092, United States
-
Decatur, Georgia
Decatur, Georgia, 30030-3438, United States
-
Flowood, Mississippi
Flowood, Mississippi, 39232-8016, United States
-
Gaithersburg, Maryland
Gaithersburg, Maryland, 20877-1409, United States
-
Garden Grove, California
Garden Grove, California, 92845-2506, United States
-
Hialeah, Florida
Hialeah, Florida, 33012-4648, United States
-
Hollywood, Florida
Hollywood, Florida, 33021-5414, United States
-
Houston, Texas
Houston, Texas, 77043-2735, United States
-
Irving, Texas
Irving, Texas, 75062-2323, United States
-
Lemon Grove, California
Lemon Grove, California, 91945-2956, United States
-
Little Rock, Arkansas
Little Rock, Arkansas, 72211-3702, United States
-
Mangonia Park, Florida
Mangonia Park, Florida, 33407-2413, United States
-
Montclair, California
Montclair, California, 91763-2231, United States
-
North Canton, Ohio
North Canton, Ohio, 44720, United States
-
Oakland Park, Florida
Oakland Park, Florida, 33334-4135, United States
-
Richardson, Texas
Richardson, Texas, 75080, United States
-
Riverside, California
Riverside, California, 92506-3257, United States
-
San Diego, California
San Diego, California, 92123, United States
-
Shreveport, Louisiana
Shreveport, Louisiana, 71101-4603, United States
-
Stara Zagora
Stara Zagora, 6003, Bulgaria
-
Veliko Tarnovo
Veliko Tarnovo, 5000, Bulgaria
-
Veliko Tarnovo, Veliko Tarnovo
Veliko Tarnovo, 5047, Bulgaria
-
Vratsa, Vratsa
Vratsa, 3000, Bulgaria